Wall Street analysts forecast that Davita Inc (NYSE:DVA) will post sales of $3.89 billion for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Davita’s earnings. The highest sales estimate is $3.99 billion and the lowest is $3.83 billion. Davita posted sales of $3.72 billion in the same quarter last year, which suggests a positive year over year growth rate of 4.6%. The company is scheduled to issue its next quarterly earnings results on Thursday, February 15th.

On average, analysts expect that Davita will report full-year sales of $3.89 billion for the current year, with estimates ranging from $15.31 billion to $15.49 billion. For the next year, analysts expect that the company will post sales of $12.05 billion per share, with estimates ranging from $11.07 billion to $13.65 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Davita.

Davita (NYSE:DVA) last released its quarterly earnings results on Tuesday, November 7th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.13). Davita had a net margin of 3.40% and a return on equity of 13.31%. The firm had revenue of $3.92 billion for the quarter, compared to the consensus estimate of $3.91 billion. During the same period in the previous year, the business earned $0.95 earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis.

A number of research analysts recently weighed in on the stock. SunTrust Banks set a $57.00 price target on shares of Davita and gave the company a “hold” rating in a research report on Sunday, October 15th. Royal Bank of Canada dropped their price target on shares of Davita from $64.00 to $60.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 8th. Bank of America reaffirmed a “buy” rating and issued a $92.00 price objective (up previously from $85.00) on shares of Davita in a research report on Thursday, January 11th. KeyCorp reaffirmed a “hold” rating on shares of Davita in a research report on Monday, November 13th. Finally, Wolfe Research raised shares of Davita from a “market perform” rating to an “outperform” rating in a research report on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and two have given a strong buy rating to the stock. Davita has a consensus rating of “Hold” and an average target price of $78.22.

Davita (DVA) opened at $78.61 on Friday. The company has a current ratio of 1.40, a quick ratio of 1.35 and a debt-to-equity ratio of 1.79. Davita has a 12-month low of $52.51 and a 12-month high of $80.71. The firm has a market cap of $14,410.00, a PE ratio of 30.12 and a beta of 0.96.

Davita announced that its Board of Directors has approved a stock repurchase program on Tuesday, October 10th that authorizes the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

In other Davita news, CEO Javier Rodriguez sold 22,532 shares of Davita stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $67.48, for a total value of $1,520,459.36. Following the sale, the chief executive officer now owns 210,317 shares of the company’s stock, valued at $14,192,191.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Leanne M. Zumwalt sold 949 shares of Davita stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $68.19, for a total transaction of $64,712.31. Following the completion of the sale, the vice president now directly owns 12,423 shares in the company, valued at approximately $847,124.37. The disclosure for this sale can be found here. In the last ninety days, insiders sold 121,509 shares of company stock worth $8,310,388. Insiders own 2.10% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of DVA. Schroder Investment Management Group increased its stake in shares of Davita by 769.0% in the third quarter. Schroder Investment Management Group now owns 434,191 shares of the company’s stock worth $25,387,000 after purchasing an additional 384,224 shares in the last quarter. Canada Pension Plan Investment Board increased its stake in shares of Davita by 14.7% in the third quarter. Canada Pension Plan Investment Board now owns 444,358 shares of the company’s stock worth $26,390,000 after purchasing an additional 56,988 shares in the last quarter. Speece Thorson Capital Group Inc. increased its stake in shares of Davita by 14.5% in the third quarter. Speece Thorson Capital Group Inc. now owns 321,182 shares of the company’s stock worth $19,075,000 after purchasing an additional 40,667 shares in the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH increased its stake in shares of Davita by 1,987.3% in the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 41,746 shares of the company’s stock worth $2,448,000 after purchasing an additional 39,746 shares in the last quarter. Finally, Oak Associates Ltd. OH increased its stake in shares of Davita by 21.1% in the second quarter. Oak Associates Ltd. OH now owns 185,195 shares of the company’s stock worth $11,993,000 after purchasing an additional 32,285 shares in the last quarter. Hedge funds and other institutional investors own 87.97% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Davita Inc (DVA) Expected to Announce Quarterly Sales of $3.89 Billion” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.dailypolitical.com/2018/01/20/davita-inc-dva-expected-to-announce-quarterly-sales-of-3-89-billion.html.

Davita Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Get a free copy of the Zacks research report on Davita (DVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.